Dr. Nicholas James Short, MD

Dr. Short practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Short's NPI, 1396039178, was assigned on June 8, 2011. Dr. Short graduated from Baylor College Of Medicine in 2011. Dr. Short's Texas license number on file is Q1745.

Dr. Short's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Short's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Short practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Short's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Short is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Short's licenses on file in 4 states: Texas, Florida, Oklahoma and Massachusetts.

Dmand AI lists anemia, bile duct problems, cellulitis, congestive heart failure, gastrointestinal infection and liver disease among the conditions Dr. Short treats.

CMS data shows 568 Medicare services from Dr. Short across 5 procedure codes in 2024, for 154 Medicare patients. Medicare paid $58,578 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 154 Medicare patients who saw Dr. Short in 2024. The largest group is 75 to 84, with 67 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 7% are also on Medicaid. Their average risk score is 3.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Short's median patient age at 69, with 49% women.

In 2024, Dr. Short wrote 213 Medicare Part D claims for 70 patients. 74% of them were for generic drugs. CMS names the drug for 73 of them, across 5 drugs with 11 or more claims each, at $129,754 in total drug cost. In 2023, CMS named 138 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Short for performance year 2024, reported as part of a group. Dr. Short accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Short as offering telehealth.

Dmand AI links 289 papers to Dr. Short, published from 2005 to 2025. 2024 was the busiest year, with 46. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Precursor Cell Lymphoblastic Leukemia-Lymphoma. Dr. Short has published most often in Am J Hematol. Dr. Short's most frequent co-authors are Hagop M. Kantarjian, MD, Tapan M. Kadia, MD and Elias J. Jabbour, MD.

Dmand AI links Dr. Short to 4 clinical trials, 2 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Hypereosinophilic Syndrome, Leukemia, Myeloid, Accelerated Phase and Leukemia, Myelomonocytic, Chronic. M.D. Anderson Cancer Center sponsors the most, 3.

CMS Open Payments shows 147 general payments to Dr. Short from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Adaptive Biotechnologies Corporation paid the most, $81,741. It also lists 3 research payments totaling $1,266 from 2018 to 2021.

Dmand AI lists 1 award for Dr. Short, most recently AOA Inductee 2011 in 2011.

Dr. Short graduated from Baylor College Of Medicine in 2011. Dr. Short is a member of AOA, ASCO and ASH.

Dr. Short is in network with 5 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.